|
AST-726 for the treatment of vitamin B12 deficiency
AST-726 is a nasally delivered form of hydroxocobalamin for the treatment of Vitamin B12 deficiency. Manhattan Pharmaceuticals acquired global rights to AST-726 as part of the recent Ariston acquisition. AST-726 has demonstrated pharmacokinetic equivalence to a marketed intramuscular injection product for Vitamin B 12 remediation. AST-726 may enable both a single, once-monthly treatment for maintenance of normal Vitamin B12 levels in deficient patients, and more frequent administration to restore normal levels in newly diagnosed B12 deficiency. Further, AST-726 could offer a convenient, painless, safe and cost-effective treatment for Vitamin B12 deficiency, without the need for intramuscular injections.
Untreated Vitamin B12 deficiency can result in serious health problems including hematological disorders, such as life-threatening anemias, and a range of central and peripheral neurological abnormalities such as fatigue, confusion, cognition impairment, dementia, depression, peripheral neuropathies and gait disturbances. Neuronal damage may involve peripheral nerves, the spinal cord and the brain, and if the condition is left untreated may become permanent.
More than 9 million people in the US are deficient in Vitamin B12, indicating substantial market potential for a facile, convenient, safe and effective treatment that can replace the need for painful and frequent intramuscular injections or other less than fully effective delivery forms. A substantial market opportunity also exists internationally.
| Copyright © Manhattan Pharmaceuticals, Inc. All Rights Reserved. Privacy Policy. |